NASDAQ:CMTA Clementia Pharmaceuticals (CMTA) Stock Price, News & Analysis → Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed! (From Priority Gold) (Ad) Free CMTA Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$26.28▼$26.6950-Day Range$26.35▼$26.3552-Week Range$8.10▼$26.73Volume716,706 shsAverage Volume145,059 shsMarket Capitalization$1.00 billionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Clementia Pharmaceuticals alerts: Email Address Ad Traders Agencytop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution… About Clementia Pharmaceuticals Stock (NASDAQ:CMTA)Clementia Pharmaceuticals Inc., a clinical stage biopharmaceutical company, develops treatments for patients suffering from bone disorders and other diseases. Its lead product candidate is palovarotene, an oral small molecule for the treatment of fibrodysplasia ossificans progressive, multiple osteochondromas, dry eye disease, and other diseases is in the Phase 3 MOVE Trial. Clementia Pharmaceuticals Inc. was founded in 2010 and is based in Montreal, Canada.Read More Ad Traders Agencytop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution… CMTA Stock News HeadlinesJanuary 6, 2022 | investing.comClementia Pharmaceuticals Inc (CMTA)See More Headlines Receive CMTA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Clementia Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/07/2018Today4/25/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:CMTA CUSIPN/A CIK1647320 Webwww.clementiapharma.com Phone514-940-3600FaxN/AEmployees30Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($7.93) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-58,130,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-44.73% Return on Assets-41.66% Debt Debt-to-Equity RatioN/A Current Ratio14.03 Quick Ratio14.03 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.18 per share Price / Book5.09Miscellaneous Outstanding Shares38,060,000Free FloatN/AMarket Cap$1.00 billion OptionableNot Optionable Beta0.64 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesDr. Clarissa Desjardins (Age 52)Founder, Pres, CEO & Director Dr. Donna Roy Grogan M.D. (Age 62)Chief Medical Officer Mr. Jeffrey Packman (Age 52)Chief Devel. Officer Mr. Steve Forte (Age 40)CFO & Corp. Sec. Mr. Joseph Andrew Walewicz (Age 50)Exec. VP of Bus. & Corp. Devel. Key CompetitorsABIVAX Société AnonymeNASDAQ:ABVXLiquidiaNASDAQ:LQDAMacroGenicsNASDAQ:MGNXInnovivaNASDAQ:INVACentessa PharmaceuticalsNASDAQ:CNTAView All Competitors CMTA Stock Analysis - Frequently Asked Questions How were Clementia Pharmaceuticals' earnings last quarter? Clementia Pharmaceuticals Inc. (NASDAQ:CMTA) issued its earnings results on Wednesday, November, 7th. The company reported ($0.46) earnings per share for the quarter, missing analysts' consensus estimates of ($0.42) by $0.04. What other stocks do shareholders of Clementia Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Clementia Pharmaceuticals investors own include Global Blood Therapeutics (GBT), Madrigal Pharmaceuticals (MDGL), JPMorgan Chase & Co. (JPM), Exelixis (EXEL), EyePoint Pharmaceuticals (EYPT), MyoKardia (MYOK), Rigel Pharmaceuticals (RIGL), Endocyte (ECYT), Amicus Therapeutics (FOLD) and Incyte (INCY). When did Clementia Pharmaceuticals IPO? Clementia Pharmaceuticals (CMTA) raised $101 million in an initial public offering (IPO) on Wednesday, August 2nd 2017. The company issued 7,200,000 shares at $13.00-$15.00 per share. Morgan Stanley and Leerink Partners acted as the underwriters for the IPO and Wedbush Securities and BTIG were co-managers. This page (NASDAQ:CMTA) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarThe A.I. story nobody is telling you (Read ASAP)TradeSmithRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldHe Is Giving Away BitcoinCrypto Swap Profitstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyYour Money is Not SafeAmerican Alternative Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Clementia Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
